Home Business GW Pharma’s Epidyolex OK’d in Australia (NASDAQ:GWPH)

GW Pharma’s Epidyolex OK’d in Australia (NASDAQ:GWPH)

85
0

GW Prescription drugs (NASDAQ:GWPH) announces that the Australian Therapeutic Items Administration (TGA) has authorized EPIDYOLEX (cannabidiol) for the remedy of seizures related to Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in sufferers two years of age and older.

LGS/DS are uncommon, treatment-resistant, extreme types of epilepsy.

GW has partnered with Chiesi Australia to make this medication obtainable in Australia, and the Firm will now work with Australia’s Pharmaceutical Advantages Advisory Committee to safe reimbursement for the medication.

The bull case for GW Prescription drugs is that they’ve a transparent path of rising present revenues within the brief time period, a promising pipeline, and cheap money reserves, writes Nick Cox in his article “GW Pharmaceuticals: A Buy After Stock Price Decline“.

In Q2, whole revenues jumped 68.5% Y/Y to $121.3M with 64.6% increase in Epidiolex sales to $117.7M vs. Q2 2019.

Wall Avenue Analysts Score is Bullish with price target of $190.69, whereas Quant Rating is Neutral.

See pharmaceutical improvement pipeline:

LEAVE A REPLY

Please enter your comment!
Please enter your name here